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Large-scale expansion of highly functional adult human mesenchymal stem cells (aMSCs) remains
technologically challenging as aMSCs lose self renewal capacity and multipotency during traditional
long-term culture and their quality/quantity declines with donor age and disease. Identiﬁcation of cul-
ture conditions enabling prolonged expansion and rejuvenation would have dramatic impact in regen-
erative medicine. aMSC-derived decellularized extracellular matrix (ECM) has been shown to provide
such microenvironment which promotes MSC self renewal and “stemness”. Since previous studies have
demonstrated superior proliferation and osteogenic potential of human fetal MSCs (fMSCs), we hy-
pothesize that their ECM may promote expansion of clinically relevant aMSCs. We demonstrated that
aMSCs were more proliferative (w1.6) on fMSC-derived ECM than aMSC-derived ECMs and traditional
tissue culture wares (TCPS). These aMSCs were smaller and more uniform in size (median  interquartile
range: 15.5  4.1 mm versus 17.2  5.0 mm and 15.5  4.1 mm for aMSC ECM and TCPS respectively),
exhibited the necessary biomarker signatures, and stained positive for osteogenic, adipogenic and
chondrogenic expressions; indications that they maintained multipotency during culture. Furthermore,
fMSC ECM improved the proliferation (w2.2), size (19.6  11.9 mm vs 30.2  14.5 mm) and differenti-
ation potential in late-passaged aMSCs compared to TCPS. In conclusion, we have established fMSC ECM
as a promising cell culture platform for ex vivo expansion of aMSCs.
 2014 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
Human mesenchymal stem cells (MSCs) are bone marrow-
derived multipotent cells which are involved in tissue regenera-
tion throughout a person’s life. Due to their self renewal capacity,
differentiation and therapeutic potential these cells are also of great
clinical interest. Currently researchers are exploring the utility ofBY-NC-ND license (http://
: (þ65) 6684 2118.
ng.chee.ping@gmail.com (C.
Published by Elsevier Ltd. All righthese cells for the treatment of many acute, chronic, and degener-
ative diseases including Crohn’s disease, multiple sclerosis, graft-
versus-host disease, type 1 diabetes, bone fractures, cartilage de-
fects, etc [1e3]. However, a major bottleneck in clinical use of adult
mesenchymal stem cells (aMSCs) is their low prevalence which
requires prolonged ex vivo expansion to achieve a useful number of
cells; expansion which results in the cells’ loss of many of their
useful stem cell properties.
The standard method of isolating and culturing aMSCs is
through plastic adherence of mononuclear cells from bone marrow
(BM) aspirate. When cultured under appropriate conditions the
aMSCs adhere and proliferate while contaminating cell types perish
resulting in a relatively pure population of progenitors after 2-3ts reserved.
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BM aspirate is small. Using colony forming unit assays (CFUs), the
prevalence of aMSCs in BM aspirates has been measured to be
between 0.001 and 0.01% of the nucleated cells within the sample
[4e6]. This means these cells must undergo prolonged expansion in
order to obtain clinically relevant cell numbers. For example, a dose
of 1e2 millions cells per kg of body weight or more (about 70e140
million cells for average human of weight 70 kg) is required for
intravenous infusion and treatment of a wide variety of conditions
such as graft-vs-host disease (GVHD), bone and cartilage defects,
myocardial infarction and autoimmune diseases [2,7].
Currently large-scale expansion of highly functional aMSCs is an
unaddressed challengeasMSCsundergodrastic phenotypic changes
during prolonged culture on tissue culture polystyrene (TCPS).
Speciﬁcally, the proliferation capacity of the cells decreases, the self
renewal capacity of the cells diminishes, and the cells often begin to
express behavior of cells with a committed lineage or reach senes-
cence. Furthermore, MSC quantity/quality declines with donor age
and disease, thus it is indeed challenging to expand sufﬁcient
numbers for treatments in older donors who are typically the pa-
tients in need of such therapy. These limitations clearly illustrate the
need to develop cell culture conditions which enable prolonged
expansion of the stem cells without loss of their stem cell charac-
teristics. One type of cell culture substratewhich has recently shows
promise inmaintaining aMSCphenotype during ex vivo expansion is
decellularized extracellular matrix (ECM). During ex vivo culture
cells produce their own ECM. Through appropriate processing the
matrix can be decellularized, meaning the cells and cellular debris
are removed leaving behind only the extracellular components.
Previously, Lin et al. showed that decellularized aMSC ECM
improved the proliferation, attachment, spread, migration, and
multi-lineage differentiation capacity of aMSCs in comparison to
cells grown in collagen type I [8]. Lai and co-workers demonstrated
the expansion of human MSCs on their ECM strongly promoted cell
proliferation, maintained stem cell properties, and resulted in low
levels of reactive oxygen species being produced [9]. In contrast,
bone formation capacity of cells expanded on tissue culture plastic
was dramatically diminished after 6e7 passages. Also, Sun et al. has
shown that culturing freshly isolated human bone marrow mono-
nuclear cells on stromal cell-derived extracellular matrix enhances
the formation of colonies comprised of either osteoblast-like,
ﬁbroblast-like, or adiopcyte-like cells [10]. In addition, they also
showed that culturing late-passageMSCs on fresh ECM recovered or
at least retained the desired properties in these older cells. These
recent studies clearly illustrated the potent ability of decellularized
ECM to maintain, and in some cases recover desirable aMSC
behavior. The cellular mechanisms which result in loss of aMSC
“stemness” during prolonged expansion remain unclear; however,
thesepreviousworks illustrate that ECMmaybean important factor.
One could envision that over multiple passages compositional
changes in ECM may occur which results in an extracellular envi-
ronment lackingcertain cuesnecessary for themaintenanceof aMSC
phenotype, and by culturing the stem cells on a more biologically
complete matrix the desired cell behaviors can be maintained/
recovered. Plating of cells on ECM isolates such as collagen or lam-
inin or synthetic substrates would likely lack the appropriate cues.
Thus, MSC ECMmay be a more biologically complete substrate and
aid in the maintenance of the desired aMSC phenotype.
In this report, we investigate the use of fMSC to generate ECM-
based substrates for ex vivo expansion of aMSCs. There are several
potential reasons why fMSC ECM may offer a superior cell growth
substrate compared to aMSC ECM and other tissue-derived MSC
ECMs. In previous work, Zhang and co-workers have illustrated
higher proliferative and osteogenic capacity of fMSC compared to
aMSCs, human umbilical cord MSCs, and human adult adiposetissue MSCs [11]. The higher proliferation capacity of the cells may
indicate greater amounts of ECM production meaning more ECM is
produced making these cells a more productive source of ECM.
Also, since the quality and quantity of MSCs has been documented
to decline with age, less ECM will be collected from cell isolated
from an adult bonemarrow sample and the ECMwhich is produced
will likely be of less consistent quality. The most primitive and
proliferative BM MSCs are from fetal bone marrow in the constant
state of tissue development indicating that they may be the best
source of ECM for the maintenance of aMSC phenotype. Further-
more, the process of decellularization destroys the cells that are
used to produce them; this implies loss of a substantial amount of
the expanded aMSCs to produce the matrix; cells which could
instead be used for therapeutics. Here, we perform 2 studies to
evaluate the utility of fMSC ECM as a cell culture substrate for the
expansion of highly functional aMSCs. First, we assess the (1)
proliferation, (2) cell size distribution (as indicators of “stemness”
[12,13]), (3) immunophenotypic expressions and (4) differentiation
capacities of expanded aMSCs seeded on fMSC ECMs in comparison
to substrates such as standard TCPS and ECMs regenerated from
aMSCs and human neonatal dermal ﬁbroblasts (nHDF). In the
second study, we explore the effects of fMSC ECMs on late-passaged
aMSCs versus TCPS in terms of the 4 parameters as indicated earlier
for the ﬁrst study. We also quantify the amount of ECM generated
from the various cell types to understand their scalability potentials
for large-scale therapeutic applications.
2. Materials and methods
2.1. Cell culture and maintenance of fMSC, nHDF and aMSC
Human fetal mesenchymal stem cells (fMSC) were isolated from fetal femurs
after clinically indicated termination of pregnancy as previously described [11]. All
human tissue collection for research purposes was approved by the Domain Speciﬁc
Review Board of National University Hospital Singapore, in compliance with inter-
national guidelines regarding the use of fetal tissue for research. In all cases, patients
gave separate written consent for the use of the collected tissue. Brieﬂy, single-cell
suspensions were prepared by ﬂushing the BM cells out of femurs using a 22-gauge
needle, passing through a 70-mm cell strainer (BD Biosciences, San Diego, CA), and
plating on Nuclon Delta T75 culture ﬂasks (Thermo Scientiﬁc Nunc, Rochester, NY)
at 106 cells/ml. Adherent spindle-shaped cells were recovered from the primary
culture after 4e7 days. Non-adherent cells were removed with initial medium
changes every 2e3 days. fMSCs were isolated and cultured in high glucose Dul-
becco’s Modiﬁed Eagle Medium (DMEM) (Life Technologies, Carlsbad, CA) for fMSC
supplemented with 10% MSC qualiﬁed fetal bovine serum (FBS) (Life Technologies,
Carlsbad, CA) and 1% penicillin/streptomycin (Life Technologies, Carlsbad, CA),
hereafter referred to as D10 medium.
Passage 2 human adult mesenchymal stem cells (aMSCs) were obtained from
Lonza (Basel, Switzerland) and cultured according to manufacturers’ instructions.
aMSC were cultured in low glucose Dulbecco’s Modiﬁed Eagle Medium (DMEM)
(Life Technologies) supplemented with 10% MSC qualiﬁed FBS and 1% penicillin/
streptomycin (Life Technologies), hereafter referred to as DLG10 medium.
Passage 1 human neonatal dermal ﬁbroblasts (nHDF, ATCC PCS-201-010)
were obtained from ATCC (Manassas, VA) and expanded according to manufac-
turers’ instructions. Neonatal dermal ﬁbroblasts were cultured and expanded to
passage 3 in Fibroblast Basal Medium (ATCC PCS-201-030) supplemented with
Fibroblast Growth Kit-Low serum (ATCC PCS-201-041) and 1% penicillin/strep-
tomycin (Life Technologies).
Cells were plated in Nuclon Delta T-75 ﬂasks at 500 cells/cm2, incubated at
37 C and 5% CO2, and medium was changed every 2e3 days. Passage 2 cultures
were expanded up to a maximum of 70% conﬂuence, detached with 1 TrypLE
Express (Life Technologies, Carlsbad, CA) unless otherwise stated and cryopreserved
in appropriate growth medium with 10% DMSO (Sigma Aldrich, St Louis, MO) and
30% MSC qualiﬁed FBS to create a stock of cells. For cell experiments, cells from the
stock were thawed and cultured according to the above protocol. Passages 4 were
used in cell experiments to screen and characterize the various substrates. D10
medium as described previously was used in all experiments.
2.2. Preparation of decellularized ECM, ﬁbronectin-coated substrates and
conditioned medium
Decellularized ECM substrates were prepared with modiﬁcations from a pre-
vious protocol [14] by plating cells in 6-well plates at 1000 cells/cm2 and cultured for
14 days with freshmedia replacement every 2e3 days (Fig. 1a). A ﬁnal concentration
of 50 mM ascorbic acid(Sigma Aldrich, St Louis, MO) was added to the media for the
Fig. 1. (a) Schematic of decellularized ECM study. MSCs are plated on TCPS and cultured to generate extracellular matrices. The MSCs are decellularized to expose the layer of ECM
for proliferation studies with aMSCs. In addition, media is collected from the fMSC cultures for the conditioned media (CM) condition. To assess proliferation, aMSCs of passage 4
were seeded on TCPS controls and decellularized matrices, cultured for 10 days before detachment to evaluate cell number and cell size. (b) Micrograph showing cell monolayer
before and after the decellularization process. The decellularization protocol successfully remove the cells leaving a layer of extracellular matrices. Scale Bar ¼ 200 mm. (c) Mi-
crographs showing adult mesenchymal stem cells cultured on the various conditions. Qualitatively, aMSCs cultured on decellularized matrices are morphologically similar to cells
cultured on TCPS. Scale Bar ¼ 200 mm. (d) Cell yield (n ¼ 3) and (e) size distribution of aMSCs cultured under various conditions. Statistical analysis with 1-way ANOVAwith Tukey’s
Multiple Comparison Test; *p  0.05, **p  0.01, ***p  0.001.
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to produce the matrices (Fig. 1b) unless otherwise stated. The cells were rinsed with
PBS and treated with PBS containing 0.5% Triton X-100 (Sigma Aldrich, St Louis, MO)
and 20 mM NH4OH (Sigma Aldrich, St Louis, MO) for 5 min at 37 C. ECM remaining
in the wells were rinsed with PBS and treated with DNAse (Sigma, 100 units/ml
PBS) for 1 h at 37 C. Following additional PBS rinsing, plates were allowed to dry
within a sterile biosafety cabinet. ECM-containing plates were stored at 4 C in the
dark in a closed sterile container or sterile sealable bag until use within 1 month.
Fibronectin-coated substrates were prepared according to Marcantonio et al.
with slight modiﬁcations [5]. Brieﬂy, ﬁbronectin (Sigma, St. Louis, MO) was adsorbed
to tissue culture substrates by incubating substrates with a 10 mg/mL solution in PBS
for 2 h at room temperature, rinsing 3 with PBS, then blocking for 1 h at room
temperature with 1% bovine serum albumin (Sigma, St. Louis, MO), and rinsing 3
again with PBS. Fibronectin coated culture wares were stored for 2e4 weeks at 2e
8 C in a closed sterile container or sterile sealable bag.
To generate conditionedmedia, fMSCs were plated at a density of 1000 cells/cm2
with D10 medium. On the following day, the medium was replaced with DLG10
medium for conditioning. The conditioned DLG10 mediumwas collected every 24 h
until the cells reached conﬂuence, sterile ﬁltered with a 0.22 mm syringe ﬁlter and
stored at 20 C until use.
2.3. Cell proliferation study
aMSC were inoculated at 100 cells/cm2 on the decelluarized fMSC ECM and
cultured for 10 days with fresh media change every 3 days. Cells were detached
using TrypLE Express or Accutase (Sigma Aldrich, St Louis, MO), samples counter-
stained with trypan blue (0.4%) (Sigma Aldrich, St Louis, MO) and counted using a
hemocytometer. Images were also acquired for cell size distribution and analyzed
using ImageJ image processing software from NIH, Bethesda, MD.
To perform cell size distribution analysis, cells monodispersed by trypsinization
was examined by cellular image analysis using ImageJ. The major and minor axes of
the cells were measured, averaged and presented as the cell sizes. Their normalized
(relative) frequency distributions, normalized against the total number of cells
counted per condition, were plotted against the average cell size (determined by
averaging the major and minor axes) in 3 mm bins. For quantiﬁcation of the cell size
distributions, the median, 25% percentile, 75% percentile and the interquartile range
(IQR, a measure of statistical dispersion equal to the difference between the upper
75% and lower 25% quartiles) of the normalized frequency distributions were
determined using GraphPad Prism 5 software (La Jolla, CA).
Cumulative population doubling level at each subcultivation was calculated
from the cell count by using the equation [15]:
NH=NI ¼ 2X ;
or
X ¼ ½log10ðNHÞ  log10ðNIÞ=log10ð2Þ;
where NI ¼ inoculum number, NH ¼ cell harvest number, and X ¼ population dou-
blings. The population doubling increase that was calculated was then added to the
previous population doubling level (PDL), to yield the cumulative population
doubling level.
2.4. Plating efﬁciency study
MSCs were harvested by trypsinization and washed twice with a serum-free
medium, and 5  104 aMSCs were inoculated per well of 2-well LabTek cham-
bered glass well slides (Thermo Scientiﬁc Nunc, Rochester, NY) prepared with the
ECM substrates. For TCPS comparison, cells were seeded on 12 wells Nunc Nuclon
Delta plates, which had an equivalent surface area (4 cm2) to the well slides. After
incubation for 2 h, the wells were rinsed twice to remove unattached cells, The
attached cells were ﬁxed using 4% paraformaldehyde (PFA) (Sigma Aldrich, St Louis,
MO) for 15 min and stained with DAPI (5 mg/ml, Life Technologies, Carlsbad, CA) for
20 min. Mosaic images of the entire wells were acquired by epi-ﬂuorescence mi-
croscopy using a customized fast-rastering Leica DMI 6000B microscope (ImageIQ,
Cleveland, OH). Cells were counted using the “analyze particles” plugin in ImageJ
image processing software (NIH, Bethesda, MD). Plating efﬁciencies (PE) measured
how efﬁcient the cells adhered to the substrates and were calculated as a fraction:
PE ¼ NA=NP
whereNA¼ adhered cell number and NP¼ plated cell number. A PE of 1 implied that
all the plated cells adhered while on the other end of the spectrum, a PE of 0 indi-
cated no adhesion.
2.5. Immunophenotyping
Tominimize the variations, theMesenchymal and Tissue StemCell Committee of
the International Society for Cellular Therapy (ISCT) has proposedminimal criteria to
deﬁne hMSC populations. These include: (i) hMSCs must be plastic-adherent when
maintained in classical culture conditions; (ii) hMSCs must express high levels
(95% positive) of CD105, CD73, and CD90 and lack expression. (2% positive) of
CD45, CD34, CD14, or CD11b, CD79a or CD19, and HLA-DR (unless stimulated byinterferon-g) surface molecules; (iii) hMSCs must differentiate into osteoblasts,
adipocytes, and chondroblasts under speciﬁc in vitro differentiation conditions
[2,16].
The various biomarkers and negative control isotypes used for screening were
purchased from BD Biosciences (San Jose, CA) and listed in Supplementary Table S1.
Some of the markers were not tested on the later passaged cells due to their limited
yield. CD14 or 11b expressionwas not also tested. Brieﬂy, cells were rinsed with PBS,
detached with accutase and incubated at 37 C in incubator for 15 min to detach
cells. Cells were washed, samples counterstained with trypan blue (0.4%) (Sigma
Aldrich, St Louis, MO) and counted using a hemocytometer. The rest of the cells were
divided appropriately into tubes containing the antibodies, mixed well and incu-
bated for 1 h in the dark. The labeled cells were washed with PBS before ﬁxation in
1% PFA, and screened using an Accuri C6 ﬂow cytometer (BD Biosciences, San Jose,
CA) within 1 week.
2.6. Differentiation assays
Osteogenesis induction was performed with StemPro(R) Osteogenesis Differ-
entiation Kit (Gibco, Life Technologies, Carlsbad, CA) according to manufacturer’s
instructions. Brieﬂy, aMSCs were plated on various substrates at 5000 cells/cm2 and
cultured in DLG10 medium for 48 h before changing to differentiation media. The
cells were subsequently cultured for 13e14 more days with media change every 3
days before detection for differentiation. Osteoblast differentiation was detected by
alkaline phosphatase (AP) expression using SIGMAFAST BCIP/NBT substrate
(Sigma Aldrich, St Louis, MO). AP activity is an indication of successful differentiation
of MSC into osteoblasts. Undifferentiated MSCs show weak alkaline phosphatase
(AP) activity, whereas differentiated osteoblasts feature very high AP and stain blue
violet using BCIP/NBT as a substrate. Cell were washed with PBS and ﬁxed with pre-
cooled methanol for 5 min at 20 C. This was followed by rinsing with mQ-H2O
before incubation with dissolved SIGMAFAST BCIP/NBT substrate for 10 min
under slow agitation on a plate shaker at room temperature. The stain solution was
removed and the cells were washed with mQ-H2O and imaged immediately while
kept moistened.
Adipogenesis induction was performed with StemPro(R) Adipogenesis Differ-
entiation Kit (Gibco, Life Technologies, Carlsbad, CA) according to manufacturer’s
instructions. Brieﬂy, aMSCs were plated on various substrates at 5000 cells/cm2 and
cultured in DLG10 medium for 48 h before changing to differentiation media. The
cells were subsequently cultured for 13e14 more days with media change every 3
days before detection for differentiation. Adipocytes were detected by their large
numbers of intracellular lipid vesicles using Oil Red O staining (Sigma Aldrich, St
Louis, MO) and identiﬁed by their bright red color. Cells were washed with PBS and
ﬁxed with neutral buffered formalin (10%) for 30 min at room temperature. This was
followed by rinsing with mQ-H2O before incubation with 60% isopropanol to cover
the cell monolayer for 5 min at room temperature. The isopropanol was replaced
with 0.3% Oil Red O in isopropanol and incubated for 20min under slow agitation on
a plate shaker at room temperature. The cells were washed with mQ-H2O and
imaged immediately while kept moistened.
Chondrogenic differentiation was done using StemPro(R) Chondrogenesis Dif-
ferentiation Kit (Gibco, Life Technologies, Carlsbad, CA) according to manufacturer’s
instructions. Brieﬂy, aMSCs were plated in non-adherent u-bottom 96-well plates at
100,000 cells/well to generate spheroids and cultured in DLG10 medium for 48 h
before a change to differentiation media. The cells were subsequently cultured for
13e14 more days with media change every 3 days before detection for differentia-
tion. Chondrogenic differentiation of MSC in 3D spheroid culture results in forma-
tion of cartilage with proteoglycan aggrecan. Aggrecan was detected with Alcian
Blue (Sigma Aldrich, St Louis, MO), a dark-blue copper-containing dye. Spheroids
were rinsed with PBS before ﬁxation with 10% neutral buffered formalin for 60 min
at room temperature. Following thorough rinsing with PBS to remove the ﬁxatives,
the spheroids were stained in 1% Alcian Blue solution in 0.1N HCl (prepared from
Alcian Blue-8GX, Sigma Aldrich, St Louis, MO) and agitated slowly on a plate shaker
for 30 min at room temperature. The spheroids were washed thoroughly with 0.1N
HCl to remove the Alcian Blue stain and imaged immediately while kept moistened.
2.7. Image quantiﬁcation of differentiation expression levels
The expression level in each image was deﬁned by the intensity density of the
stain in the image, which is the product of area and mean intensity of the stains in
the images. This was determined using ImageJ by adopting the methods from their
online example provided to quantify stained liver tissues (http://rsbweb.nih.gov/ij/
docs/examples/stained-sections/index.html). Brieﬂy, there were ﬁve steps to
obtaining the quantiﬁcation:
(1) converting the color images to grayscale images of individual red, green and
blue channels,
(2) determining the channel with the best separation (BCIP NBT and Oil Red Oe
green channel; Alcian Blue e red channel)
(3) isolating the stained areas using thresholding and converting the thresh-
olded portion of the image into a selection mask using the ‘create selection’
function
(4) transferring the selection mask back to the original color image
C.P. Ng et al. / Biomaterials 35 (2014) 4046e40574050(5) measuring the intensity density of the selection in the image using the
’measure’ function
The ImageJ macro for the BCIP NBT expression quantiﬁcation is provided in the
supplementary materials as an example (Supplementary Fig. S1).
2.8. Late passage study
In the late passage studies to assess if fMSC ECM substrates could rejuvenate aged
aMSCs (Schematic in Fig. 5a), Passage 6 cells previously cultured onTCPSwere seeded
on fMSC ECM substrates at 100/cm2 and cultured in similar conditions for 3 passages
as stated above. They are then assessed for cell proliferation, cell size, differentiation
capabilities and MSC biomarker expression as described in the earlier sub-sections.
2.9. Quantiﬁcation of ECM yield per cell plated
Decellularized ECM substrates were prepared as described in Section 2.2. The
substrates were mechanically detached in deionized water using cell scrapers (SPL
Life Sciences, South Korea) and weighing them in 1.5 ml eppendorf tubes (pre-
weighed and post-dried after drying in a 70 C oven overnight). The weight of the
ECM was normalized to the number of cells plated instead of the number of cells at
the time of decellularization since it was not possible to determine the latter number
due to the destructive nature of the decellularization protocol. In addition, from a
scalability perspective, it might be more of interest to determine how much ECM
could be generated from the number of cells plated instead.
2.10. Statistical analysis
All data are presented as mean  standard deviation calculated, with n ¼ 3 rep-
licates or otherwise stated, depending on the experiments. Using GraphPad Prism 5
software,multiplemeanswere comparedwith either an unpaired t-test or an analysis
of variance (ANOVA) test to determine if the means were statistically different. If
ANOVA indicated statistical difference, then the TukeyeKramer Honestly Signiﬁcant
Difference Test was used to determine which of the pairs of means were statistically
different. Pairs of means are marked with either (ns) meaning the means or not sta-
tistically differentor asterisks (*) if themeans are signiﬁcantly different. Thenumberof
asterisks indicates the P-value: p  0.5 for *, p  0.01 for **, and p  0.001 for ***.
3. Results
3.1. Effect of proliferation of aMSCs on various substrates
We ﬁrst started by screening various substrates and conditions,
speciﬁcally, conditioned medium using expanded passage 4 aMSCs
(Fig. 1a). Passage 3 cells were used to prepare the decellularized
matrices unless otherwise stated. They were successfully decellu-
larized as visualized by lightmicroscopy (Fig.1b). The reason for the
choice of passage 3 was to maximize the number of cells while
ensuring the cells still maintain their undifferentiated phenotypes.Fig. 2. Plating Efﬁciency of expanded adult mesenchymal stem cells. Cells were plated
at 5.0  104 per well and incubated for 2 h before rinsing to ﬁxation. Fixed cells were
stained with DAPI(5 mg/ml) for 15 min, imaged and counted using ImageJ. Statistical
analysis using 1-way ANOVA with Tukey’s Multiple Comparison Test; ***p  0.001.Furthermore, early passage BM cultures contained contaminated
non-MSCs of mostly hematopoietic nature that usually cleared up
within the 2 passages. It had also been shown by Binato and co-
workers that MSCs retain their chromosome stability up to pas-
sage 4 [7]. Morphologically, aMSCs cultured on fMSC ECM retained
spindle-shaped morphology (Fig. 1c) but qualitatively more in
numbers. They also appeared more aligned, probably due to the
orientation of the fMSC ECM. aMSCs cultured on fMSC P3 ECM
resulted in signiﬁcantly higher growth than on TCPS as indicated by
the cell yield at day 10 (Fig. 1d). On average, the cell number at the
end of day 10 culture on fMSC ECM is about 1.6 more than their
TCPS counterpart (n ¼ 3, p  0.01). In addition, the passage/age of
the cells used for generating the matrices appear to affect the
quality of the ECM as P4 fMSC ECM were less effective compared to
P3 fMSC ECM. Growth on P4 ECMwas also higher (about 1.3) than
that of TCPS (n ¼ 3, p > 0.05) but lower than culture on P3 ECMs.
aMSCs cultured on fMSC ECMs were also more proliferative (about
1.8) than their counterparts on aMSC ECMs. Interestingly here, we
did not observed any signiﬁcant difference (p > 0.05) between
aMSC yield on aMSC ECMs in comparison to TCPS.
Fromthe cell sizedistributiondata (Fig.1e andTable1) in termsof
median and interquartile range (IQR), we observed that aMSCs
cultured on P3 fMSC ECM (median  IQR: 15.5  4.1 mm) have
slightly smaller and more uniform sizes than TCPS (17.5  4.4 mm)
and others (e.g. aMSC ECM: 17.2  5.0 mm; P4 fMSC ECM:
18.5  5.3 mm; Fibronectin: 22.4  11.5 mm). It has been demon-
strated that smaller MSCs share similar characteristics as early
passage multi-potent MSCs and may be more “stemness” [12,13].
Thus the result here may suggest that culturing aMSCs on the fMSC
ECMs may help the adult cells to retain their “stemness”
characteristics.
In addition in a separate screening, we investigated the ECM of
neonatal ﬁbroblasts (nHDF) for the expansion of aMSCs in compar-
ison toTCPS (Supplementary Fig. S2). Fibroblast ECMs are of interest
since they are one of the substrates used for expanding stem cells.
While aMSCs proliferated more (about 1.7 fold) on nHDF ECM
compared toTCPS (Supplementary Fig. S2a), the cell sizedistribution
for the aMSCs cultured on both substrates are similar however
(Supplementary Fig. S2b). Furthermore, we tested some of the
commercially available xenogenic-free substrates (Supplementary
Fig. S3). However, the proliferation and size of the aMSCs on these
substrates were not signiﬁcantly improved and in some conditions,
performed worse than our control TCPS substrates. Since the ﬁbro-
nectin coating, conditioned media conditions and xenogenic-free
substrates did not improve or fared signiﬁcantly worse than TCPS
in terms of cell yield (Fig. 1d, n ¼ 3, p < 0.001 and p < 0.05 for
ﬁbronectin and conditionedmedia respectively and Supplementary
Fig. S2 for xenogenic-free substrates) and size (Table 1 and
Supplementary Fig. S2), we did not include them in subsequent
evaluations, which we focused on the ECM substrates.
3.2. Plating efﬁciency
All the ECM substrates (aMSC, fMSC and nHDF) were very
effective in capturing the aMSCs within 2 h (Fig. 2), with plating
efﬁciencies around 1 (Mean  S.D: 0.94  0.09, 1.07  0.08,
1.03  0.06 for aMSC, fMSC and nHDF respectively, n ¼ 4 for all). In
contrast, the performance of glass substrateswere signiﬁcantly poor
(0.270.06, n¼ 6)while TCPSwere efﬁcient (0.60 0.06, n¼ 4) but
still signiﬁcantly less than the ECM substrates (p < 0.001).
3.3. Flow cytometry analysis
hMSCs must express high levels of CD73, CD90, CD105 and lack
expression of CD45, CD34, CD79a and HLA-DR, as deﬁned by the
Fig. 3. Flow cytometry analysis of MSC markers for aMSCs cultured on TCPS (a-i and a-ii for MSC positive and negative markers respectively) and fMSC ECM (a-iii and a-iv for
positive and negative markers respectively) with the particle count on the y-axes (0e800 in intervals of 200) and the ﬂuorescence intensity data in terms of particle area (FL-A) on
the x-axes (in log 10 scale from 101 to 107.2) and (b) surface biomarker expression of aMSC cultured on various substrates.
C.P. Ng et al. / Biomaterials 35 (2014) 4046e4057 4051Mesenchymal and Tissue Stem Cell Committee of the ISCT [16]. Our
results in Fig. 3 shows that similar to their counterparts cultured on
TCPS, aMSCs retain their immunophenotype when cultured on
fMSC ECM.3.3. Differentiation assay
We have also demonstrated through in vitro assays that aMSCs
plated on fMSC ECM are multi-potent as they are able to
Fig. 4. Differentiation assays of aMSCs (P3 or P4) cultured on TCPS and fMSC ECM (a for osteogenesis, b for adipogenesis and c for chondrogenesis). For negative controls, aMSCs are
cultured in growth media. The purple positive stain in the micrographs are of alkaline phosphate expression after 14 days of selection pressure and evaluated using SIGMAFAST
BCIP/NBT. Adipocytes are stained positively with Oil Red O and can be identiﬁed by their bright red color. Cartilage formation was detected with Alcian Blue, which stains aggrecan,
an ECM component produced, dark blue. Quantiﬁcation of differentiation expression levels of aMSC cultured on various substrates. The expression level is deﬁned by the intensity
density, as calculated by taking the product of the area and the mean of the stains in the images. Scale Bar ¼ 200 mm.
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Fig. 5. (a) Schematic of late passage TCPS-cultured aMSC study, (b) Cell numbers (n ¼ 3), (c) size distribution, and (d) surface biomarker expressions of late passage (P6) TCPS-
cultured aMSCs that have been cultured under TCPS and FMSC ECM for 3 passages. Signiﬁcant increase in cell proliferation observed as ascertained using 2-tailed unpaired t-
test, **p  0.01.
C.P. Ng et al. / Biomaterials 35 (2014) 4046e4057 4053differentiate into osteogenic, adipogenic and chondrogenic lineages
based on positive alkaline phosphatase (AP) (purple stain in
Fig. 4a), oil red o (red stain in Fig. 4c) and alcian blue (blue stain in
Fig. 4e). The expression levels of the various stains in the images
were quantiﬁed and presented as intensity densities (Fig. 4b, d and
f). For osteogenic differentiation, the AP expression levels of aMSCs
differentiated on aMSC ECM and fMSC ECMs were signiﬁcantly
higher (p  0.01, w1.6 and w1.7 respectively, n ¼ 19 and 15
respectively) than that of their controls on TCPS (n ¼ 15) (Fig. 4b).
Interestingly, the AP levels for aMSC on nHDF ECMs were signiﬁ-
cantly poor compared to the other conditions (p  0.001, w9.3,
9.5 and 5.7 lower to aMSC ECM, fMSC ECM and TCPS respec-
tively, n ¼ 15). For adipogenic differentiation (Fig. 4d), only the Oil
Red O expression levels of the cells differentiated on fMSC ECM
were signiﬁcantly higher to their TCPS counterparts (p  0.05,
w9.3, n ¼ 15 for both). The average expression levels of aMSCs on
the other ECMs were higher (w3.0 andw2.4 for aMSC ECM and
nHDF ECM respectively, n¼ 15 for all) but not signiﬁcantly different
to that of TCPS (p> 0.05), suggesting that adipogenic differentiation
potential of aMSCs were better retained when cultured on ECM
substrates. Furthermore, the average Alcian blue expression levels
for all ECM conditions were similar and higher than the TCPSTable 1
Size distribution characteristics of aMSCs cultured on the various substrates and conditi
aMSC P3 ECM TCPS F
Median (mm) 17.2 17.5 2
25e75% percentile (mm) 15.7e20.7 15.8e20.2 1
Interquartile range (IQR) (mm) 5.0 4.4 1(w1.4, w1.4 and w1.3 for aMSC ECM, fMSC ECM and nHDF
ECM respectively) but they were not signiﬁcantly different
(p> 0.05, n¼ 5, 21, 20 and 20 for aMSC ECM, fMSC ECM, nHDF ECM
and TCPS respectively) (Fig. 4f). The quantitative results here agreed
with our qualitative observations that multi-potency of the aMSCs
are better retained on fMSC ECM in contrast to their counterparts
on TCPS and aMSC ECM. They also suggested that the fMSC ECM
might be a superior, if not comparable, platform to TCPS for the
culture of aMSCs.
3.4. Effect of plating late-passaged TCPS-cultured cells on fMSC
ECM
To elucidate if late-passaged cells can be “rejuvenated” by fMSC-
derived ECM, we took aMSCs that had been cultured on TCPS for 6
passages and plated them on fMSC ECM. After 3 passages, we
assessed their cell yield, cell size and osteogenic potential in com-
parison to their TCPS counterpart (Fig. 5a). We observed signiﬁ-
cantly higher cell numbers (about 2.2-fold, p  0.01, n ¼ 3)
compared to TCPS controls (Fig. 5b). In addition, culturing late
passage aMSCs on fMSC ECM (labeled TCPS-FMSC ECM in the
ﬁgure) retarded but did not prevent their gradual increase in celloned media (CM).
ibronectin fMSC P2 CM fMSC P3 ECM fMSC P4 ECM
2.4 22.5 15.5 18.5
7.9e29.4 20.0e26.5 13.9e18.0 15.3e18.5
1.5 6.5 4.1 5.3
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for TCPS-FMSC ECM-cultured cells (P9) increased to 19.6  11.9 mm
(Median  IQR) in contrast to the size distribution of the starting
passage (P6, 16.8  5.9 mm) (Table 2). In comparison, the TCPS-
cultured cells (P9) had a higher median and wider distribution of
30.2  14.5 mm. Furthermore, higher frequency of TCPS-FMSC ECM
cultured cells (about 20% compared to about 10% for TCPS-cultured
cells) was observed to possess similar cell size distribution in the
5e20 mm range compared to the starting passage (P6, green, about
40% in Fig. 5c). Main positive and negative biomarkers were
screened for the 2 culture conditions (Fig. 5d) and their expressions
were comparably similar. One exceptionwas that CD105 expression
of late-passaged TCPS-FMSC cultured aMSCs were lower than that
of TCPS cultured aMSCs (74.4% vs 86.0%).
Interestingly, TCPS-FMSC ECM cultured cells improved their
differentiation potential in contrast to TCPS-cultured cells as evi-
denced by the positive stain expressions after application of differ-
entiationmedia (Fig. 6a). In addition, their average expression levels
were higher compared to the TCPS-cultured counterparts. Quanti-
ﬁcationof theAP levels using SIGMAFASTBCIPNBT for TCPS-FMSC
ECM cultured cells showed higher but not signiﬁcantly different
expression (w1.6, p > 0.05, n ¼ 9) to the TCPS-cultured controls
(Fig. 6b). Oil Red O intensity densities were signiﬁcantly higher for
adipogenic differentiated TCPS-FMSC ECM cultured cells compared
to TCPS-cultured cells (w2.1, p  0.05, n ¼ 7 and 11 respectively).
Furthermore, we found that there was a trend towards higher but
not signiﬁcantly different intensity densities of chondrogenic
(Alcian Blue) expression for TCPS-FMSC ECM cultured cells in
comparison to the TCPS-cultured cells (w18.7, > 0.05, n¼ 5 and 6
respectively). In addition, virtually all TCPS-cultured cells lost their
chondrogenic potential as indicated by their Alcian Blue expression
(Fig. 6a and b). Taken together, the study with late-passaged TCPS-
cultured cells suggested the ability of the fMSC ECM to retard the
senescence and rejuvenate the “stemness” of expanded aMSCs.
3.5. Quantiﬁcation of ECM yield
Lastly to understand the scalability potential of the substrate for
large-scale expansion of aMSCs for therapeutic applications, we
quantiﬁed the amount of ECM produced per cell plated. We ob-
tained (0.5 0.2) mg, (1.4 0.6) mg and (0.6 0.5) mg per cell plated
for aMSC (n ¼ 6), fMSC (n ¼ 4) and nHDF (n ¼ 6) respectively
(Fig. 7). The ECM yield for fMSC is signiﬁcantly higher than aMSC
(p  0.05). In addition, the yield for fMSC was also higher to that of
nHDF but not signiﬁcantly different (p > 0.05).
4. Discussion
Traditionally, MSC cells are expanded on tissue culture poly-
styrene (TCPS). However, they lose their regenerative capabilities
after a few passages. Furthermore, results vary depending on the
quality and brand of tissue culture polystyrene used [17]. To over-
come these shortfalls, others have deposited individual ECM pro-
teins such as ﬁbronectin, collagen or laminin on the plastic
substrates to culture and expand aMSCs. Recent alternatives are theTable 2
Size distri4bution characteristics of late passage TCPS-cultured aMSCs cultured on
FMSC ECM in comparison to TCPS.
TCPS (P6) e
starting
passage
TCPS (P9) TCPS-FMSC
ECM (P9)
Median (mm) 16.8 30.2 19.6
25e75% percentile (mm) 14.5e20.4 21.3e35.7 14.5e26.3
Interquartile range (IQR) (mm) 5.9 14.5 11.9development of xenogenic-free substrates, which includes syn-
thetic polymers or/and recombinant human matrices or matrix
isoforms [2,3,18,19]. Many have become commercially available in
recent years or are in the process of development. One of the
drawbacks in growing cells in vitro using conventional tissue cul-
ture techniques and other above mentioned substrates is that these
culture environments do not mimic their natural biological support
enough or adequately in the physiological relevant manner. This
natural support is a complex network of numerous macromole-
cules known as the extracellular matrix or ECM. The ECM holds
cells and tissues together and provides a highly organized lattice
within which cells can migrate and interact with each other. The
matrix also plays an active and complex role in regulating the
behavior of cells that are in contact with it, inﬂuencing their shape,
migration, proliferation and metabolic functions [20,21]. Some of
the ECM proteins found in the MSC ECMs are Collagen Type I,
Collagen Type III, Fibronectin, Biglycan, Decorin, Perlecan and
Laminin [9]. In contrast, cells grown on plastic and isolated proteins
lose many of their natural multipotent properties since this
approach fails to accurately mimic the complex protein interaction
with the endogenous ECM, an environment that can be efﬁciently
generated by a number of cellular populations.
The design of niche-like cell culture interfaces that maintain
cells in their native behavioral state or instruct their phenotypic
transformation towards that of a desired tissue may be the key to
expanding MSC effectively. It has been previously demonstrated
that cells cultured on ECM adopt growth characteristics, morpho-
logical appearance and biological responses which were not
expressed when maintained on artiﬁcial plastic or glass substrata.
This was observed even if the same substrates were coated with
isolated constituents of ECM such as puriﬁed collagen or glyco-
proteins [22e26]. In recent years, therewere studies that employed
decellularized matrices from epithelial cells, endothelial cells, ﬁ-
broblasts and adult bone marrow mesenchymal stem cells to
expand the MSCs [8,9,14,27,28]. These studies concluded that
decellularized matrices offer superior platforms to proliferate the
cells in contrast to traditional methods. The use of naturally pro-
duced ECM, may also assure that the various matrix components
will be found in their natural conﬁguration and proportion. In this
report, we investigated employing employing fMSCs, the most
primitive and generative versions of MSCs, to produce the matrices
for culturing the adult mesenchymal stem cells. Being similar cell
types (except this is the fetal version), we hypothesized that their
microenvironment would be the most similar, and therefore the
most suitable for culturing these cell types. Furthermore, the pro-
cess of decellularization destroyed the cells used to produce the
matrices. Thus if autologous adult mesenchymal stem cells were
used to generate the ECM, a large portion of the cells would be
destroyed during the process resulting in the sacriﬁce of the
already limited aMSCs. An alternative would be to rely on alloge-
neic sources for preparing the substrates. However, aMSCs suffered
from more inconsistency since proliferation capacity and multi-
potency depended on the age/health of the donor. Furthermore,
fMSC had been demonstrated to possess higher proliferative and
osteogenic capacity compared to aMSCs and MSCs from other
sources [11]. This implied that their ECM might be a superior
substrate to expand and perhaps regenerate the stem cell behavior
of adult cells. In addition, we might be able to generate larger
quantities of ECM due to their superior growth. We observed here
that only the decellularized fMSC matrices had shown signiﬁcant
increase in numbers of aMSC compared to TCPS during expansion.
In contrast to previous literature [8,9], we did not observed
increased proliferation on aMSC ECM in comparison to TCPS. It was
possible that the TCPS substrates employed in our studies were
more conducive for the expansion of aMSCs compared to those
Fig. 6. (a) Representative differentiation micrographs and (b) expression levels of late passage (P6) TCPS-cultured aMSCs that have been cultured under TCPS and FMSC ECM for 3
passages. The purple positive stain in the micrographs are of alkaline phosphate expression after 14 days of selection pressure and evaluated using SIGMAFAST BCIP/NBT. Adipocytes
are stained positively with Oil Red O and can be identiﬁed by their bright red color. Cartilage formation was detected with Alcian Blue, which stains aggrecan, an ECM component
produced, dark blue. The expression level is deﬁned by the intensity density, as calculated by taking the product of the area and the mean of the stains in the images. Scale
bar ¼ 200 mm.
Fig. 7. ECM yield per cell plated. Statistical analysis using 1-way ANOVA with Tukey’s
Multiple Comparison Test; *p  0.05.
C.P. Ng et al. / Biomaterials 35 (2014) 4046e4057 4055used by others in previous literature; studies have shown that
aMSCs plated on TCPS of various brands could vastly differ in their
isolation, expansion and characteristics [17,29]. Alternatively, the
aMSCs used in our studies might not be as potent (which according
to the manufacturer, our lot was isolated from a 43-year old male
donor and estimated to had undergone 7e8 population doublings
by passage 2; a further 7 doublings before they were used to
generate the substrates) as their equivalents used in previous
studies. Interestingly as well, we obtained higher ECM yield from
fMSC compared to the other cell types (aMSCs and nHDFs) (Fig. 7);
this ﬁnding might explain why we experienced higher cell yield
when aMSCs were expanded on ECM generated from the fMSCs as
the increased ECM yield might contain higher amount of seques-
tered growth factors and provide a more conducive environment
for proliferation. Our results thus suggested that fMSC ECMs as
promising substrates to improve the ex vivo expansion of aMSCs for
potential autologous applications such as clinical transplantation.
However, this needs to be further validated through several
different fMSC lines in order to reafﬁrm and improve the power of
our observations. In addition, further studies as described below
will be necessary to optimize the ECM substrates for translational
applications.
C.P. Ng et al. / Biomaterials 35 (2014) 4046e40574056Since the studies here were performed on mid-passages cells,
one of the future studies is to culture the cells from the point of
isolation where mononuclear cells from fresh bone marrow aspi-
rates to their senescence to elucidate the long term effectiveness of
the ECM substrates on expansion and maintenance of their prog-
eny. We had performed a long-term study where we cultured and
tracked the cell yield over 5 passages until the cultured aMSCs
reached senescence. Commercially available cryopreserved puriﬁed
aMSCs were plated directly on the various substrates and replated
on the same kind of substrates after 10 days of expansion. We
observed the loss of aMSC proliferation capacity and “stemness” in
the later passages for all conditions and surprisingly, aMSCs
reached senescence faster when cultured on fMSC ECM compared
to TCPS and other substrates (data not shown). In addition in this
study, long term culturing on fMSC ECM also did not maintain the
multipotency of the aMSCs as we observed an increase in the cell
size distribution. However, it was possible that our long term study
was not conducted optimally. For example, we cultured them for 10
days before passaging; this usually resulted in almost conﬂuent
conditions (beyond the recommended 70%) for the aMSCs cultured
on fMSC ECM in contrast to the other substrates due to its higher
proliferative capacities in the early passages. As a result, this might
have caused the cells to lose their proliferative potential and reach
senescence faster in the later passages. To ascertain if this is the
case, it will be interesting to repeat the long term studies but
passage the cells at 70% conﬂuency instead of every 10 days.
Alternatively, the results may suggest that there are limitations to
the life span of the aMSC population and culturing them under any
of the tested ECM substrates will not extend their life spans. In
addition, commercial available expanded aMSCs were used in the
studies. Their preparation, expansion and cryopreservation
methods may already committed some of the progenitors down
certain lineages and may affect their subsequent fates on these
substrates [30,31]. Indeed, we failed to detect one of the early
positive biomarkers, particularly CD271 [32e35], in the early pas-
sages (Fig. 3).
Furthermore, our results (Fig. 1) indicated a passage-
dependence on the quality of the ECM with the passage 3 ECM
substrates performing better than ECM generated from Passage 4 in
terms of cell yield and size. Therefore, we may to eludicate the
effects of ECM produced by earlier passage (1 and 2) fMSCs. In
addition, earlier passage cell populations contained contaminating
cells from their isolation such as hematopoietic cells. The ECM of
these contaminating cells might synergistically provide a more
supportive environment on maintaining the multipotency of the
MSCs. However, these series of studies may face difﬁculties to
implement and may also not be feasible in terms of scaling up for
applications due to limitations in their cell numbers.
Lastly, the ECM substrates were generated by culturing the cells
to conﬂuence and maintaining them under conﬂuence conditions
for one more week. This method from previous decellularization
protocols for aMSC ECMs [8,9,14] were based on protocols from
studies using epithelial and endothelial cells [36]. Culturing to
conﬂuence and beyond might not be ideal for MSCs since it was
generally recommended to passage these cells at 70e80% conﬂu-
ence for optimal growth and prevent them from becoming senes-
cent and lose pluripotency. The conﬂuency of the MSCs might alter
their phenotypes, and thereby changing the nature of the ECM they
produced to one that is more committed towards certain lineages
or provide cues for senescence. Therefore for it would be inter-
esting to investigate the ECM generated during the growth phase.
In addition, we noticed that the ECM may delaminate easily during
the rinsing and treatment steps in our decellularization protocol;
this was previously by others using similar decellularization pro-
tocols [37]. While weminimized the delamination through delicatehandling of our ECM culture wares, it may be necessary to improve
the adhesion of the ECM to substrate through immobilization [37].
Alternatively, since the quantity produced may be limited, it might
be necessary to develop transferable versions by retrieving and
pooling the decellularized matrices to obtain sufﬁcient amounts for
testing. Nevertheless, our results overall represented the ﬁrst steps
towards the potential use of fMSC ECMs to improve the expansion
andmaintenance of aMSCs. To our knowledge, this is the ﬁrst study
in which matrices derived from BM fMSCs were generated and
characterized for their expansion and differentiation potential.
More studies, such as genetic stability characterizations, will be
required to better understand the biological effects of aMSCs cul-
tures under fMSC ECMs and translate the fMSC ECM substrate to
expand aMSCs ex vivo for clinical applications.
5. Conclusions
In summary, fMSC ECM promotes aMSC expansion better than
the other conditions including TCPS, aMSC ECM and nHDF ECMs in
terms of superior growth, smaller and more uniformed-sized cells.
This phenomenon may be dependent on the age (passage number)
of the cells producing the substrate. Late-passage aMSCs (previ-
ously cultured on TCPS for 5 passages) were signiﬁcantly improved
on the fMSC ECM platform in terms of proliferation, stemness and
differentiation potential compared to continuous culture in stan-
dard TCPS conditions. We also quantiﬁed amount of ECM produced
by each plated cell, which suggested feasible scalability for clinical
applications. The results established fMSC matrices as promising
platforms for ex-vivo expansion of human aMSCs.
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